Luvastab- 40
A Highly Attractive Option For ASCVD


Composition : Fluvastatin 40mg

Form : Tablets / Pack : 1 X 10's / Type : AA

Description : One‐hundred and forty‐five trials (36 placebo controlled and 109 before and after) evaluated the dose‐related efficacy of fluvastatin in 18,846 participants. The participants were of any age with and without evidence of cardiovascular disease, and fluvastatin effects were studied within a treatment period of three to 12 weeks. Log dose‐response data over doses of 2.5 mg to 80 mg revealed strong linear dose‐related effects on blood total cholesterol and LDL cholesterol and a weak linear dose‐related effect on blood triglycerides. There was no dose‐related effect of fluvastatin on blood HDL cholesterol. Fluvastatin 10 mg/day to 80 mg/day reduced LDL cholesterol by 15% to 33%, total cholesterol by 11% to 25% and triglycerides by 3% to 17.5%. For every two‐fold dose increase there was a 6.0% (95% CI 5.4 to 6.6) decrease in blood LDL cholesterol, a 4.2% (95% CI 3.7 to 4.8) decrease in blood total cholesterol and a 4.2% (95% CI 2.0 to 6.3) decrease in blood triglycerides. The quality of evidence for these effects was judged to be high - Cochrane Database of Systematic Reviews - Published : 06 March 2018

View more products with following salts

Atorts-40
Assured Lipid Management Regimen


Composition : Atorvastatin 40mg

Form : Tablets / Pack : 1 X 10's / Type : AA

Description : Atorvastatin is an appropriate first-line lipid-lowering therapy in numerous groups of patients at low to high risk of CHD. Additionally it has a definite role in treating patients requiring greater decreases in LDL-cholesterol levels. Long-term studies are under way to determine whether achieving very low LDL-cholesterol levels with atorvastatin is likely to show additional benefits on morbidity and mortality in patients with CHD - Drugs. 2001;61(12):1835-81.

View more products with following salts

Atorts-20
Assured Lipid Management Regimen


Composition : Atorvastatin 20mg

Form : Tablets / Pack : 1 X 10's / Type : AA

Description : Atorvastatin is an appropriate first-line lipid-lowering therapy in numerous groups of patients at low to high risk of CHD. Additionally it has a definite role in treating patients requiring greater decreases in LDL-cholesterol levels. Long-term studies are under way to determine whether achieving very low LDL-cholesterol levels with atorvastatin is likely to show additional benefits on morbidity and mortality in patients with CHD - Drugs. 2001;61(12):1835-81.

View more products with following salts

Atorts-10
Assured Lipid Management Regimen


Composition : Atorvastatin 10mg

Form : Tablets / Pack : 1 X 10's / Type : AA

Description : Atorvastatin is an appropriate first-line lipid-lowering therapy in numerous groups of patients at low to high risk of CHD. Additionally it has a definite role in treating patients requiring greater decreases in LDL-cholesterol levels. Long-term studies are under way to determine whether achieving very low LDL-cholesterol levels with atorvastatin is likely to show additional benefits on morbidity and mortality in patients with CHD - Drugs. 2001;61(12):1835-81.

View more products with following salts

Pitsafe Plus
When Fail To Tolerate Current Drug Therapy


Composition : Pitavastatin 4mg Plus Ezetimibe 10mg

Form : Tablets / Pack : 1 X 10’s / Type : Alu Alu

Description : The use of statins is essential for aggressive lipid-lowering treatment in acute coronary syndrome (ACS) patients with dyslipidemia. Recently, elevation of sitosterol, a lipid absorption marker, was reported to be associated with premature atherosclerosis. The purpose of the present study was to examine the impact of ezetimibe, a selective intestinal cholesterol transporter inhibitor, in ACS patients.

Methods: A total of 197 ACS patients were randomized to pitavastatin + ezetimibe or pitavastatin. Low-density lipoprotein cholesterol (LDL-C) and sitosterol levels were evaluated on admission and after 12 weeks.

Results: After 12 weeks, the pitavastatin + ezetimibe group showed a significantly greater decrease of sitosterol (baseline versus after 12 weeks; 2.9 ± 2.5 versus 1.7 ± 1.0 ng/mL, ) than the pitavastatin group (2.7 ± 1.5 versus 3.0 ± 1.4 ng/mL). The baseline sitosterol level was significantly higher in patients with achieved LDL-C levels ≥ 70 mg/dL than in patients with levels < 70 mg/dL (3.2 ± 2.5 versus 2.4 ± 1.3 ng/mL).

Conclusions: Ezetimibe plus statin therapy in ACS patients with dyslipidemia decreased LDL-C and sitosterol levels more than statin therapy solo. Sitosterol Elevation was a predictor of poor response to aggressive lipid-lowering treatment in ACS patients- Journal of Lipids, Volume 2015 (2015); page 8.For Aar Ess Remedies Pvt. Ltd.

View more products with following salts

Pitsafe-4
The 7th Statin For More Tolerability


Composition : Pitavastatin 4mg.

Form : Tablets / Pack : 10 x 10's / Type : ALU-ALU

Description : Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option; Pitavastatin may reduce the risk of heart attack, stroke and even death up to 68 percent of patients. More than 20,000 patients with hypercholesterolemia who were treated with pitavastatin for up to 2 years, the LDL-C (low-density lipoprotein cholesterol) target rate recommended by the Japanese Atherosclerosis Society (JAS) was achieved by 88.2% of low-risk patients (<160 mg/dL), 82.7% of intermediate-risk patients (<140 mg/dL), 66.5% of high-risk patients (<120 mg/dL), and 50.3% of secondary prevention patients (<100 mg/dL). In patients with low HDL-C, a significant reduction of total cholesterol (TC; -21.0%), LDL-C (-31.3%), and triglyceride (TG) (-6.1%) was seen at 104 weeks- Int J Clin Pract. 2005 Feb;59(2):239-52.

View more products with following salts

Pitsafe-2
The 7th Statin For More Tolerability


Composition : Pitavastatin 2mg.

Form : Tablets / Pack : 10 x 10's / Type : ALU-ALU

Description : Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option; Pitavastatin may reduce the risk of heart attack, stroke and even death up to 68 percent of patients. More than 20,000 patients with hypercholesterolemia who were treated with pitavastatin for up to 2 years, the LDL-C (low-density lipoprotein cholesterol) target rate recommended by the Japanese Atherosclerosis Society (JAS) was achieved by 88.2% of low-risk patients (<160 mg/dL), 82.7% of intermediate-risk patients (<140 mg/dL), 66.5% of high-risk patients (<120 mg/dL), and 50.3% of secondary prevention patients (<100 mg/dL). In patients with low HDL-C, a significant reduction of total cholesterol (TC; -21.0%), LDL-C (-31.3%), and triglyceride (TG) (-6.1%) was seen at 104 weeks- Int J Clin Pract. 2005 Feb;59(2):239-52.

View more products with following salts

Pitsafe-FB
Who can't tolerate the side effects of statins


Composition : Pitavastatin 2mg + Fenofibrate 67.5mg

Form : Tablets / Pack : 10’s / Type : ALU-ALU

Description : Co-administration of pitavastatin and fenofibrate should be considered as one of the options for the treatment of hypercholestrolemic patients with hupertriglyceridemia, in whom, control of the lipid profile sometimes becomes problematic in routine clinical practice - Japanese Clincal Medicine 2011:2 57-66 Pitvastatin and atorvastatin cuased significant and almost comparable reductions in serum levels of total cholesterol (-35.4 vs -33.8%), low-density lipoprotein cholesterol (-42.8 vs.-40.7%), and triglyceride (-26.1 vs -29.4%) and significantly increased serum levels of high-density lipoprotein cholesterol (12.1 vs 11.4%). Under these conditions, plasma levels of CoQ10 were reduced by atorvastatin (-26.1%, P=0.0007) but not by pitavastatin (-7.7%, P=0.39) - Clin Pharmacol Ther, 2008 May;83(5):731-9

View more products with following salts

Pitsafe-EZ
The 7th statin for more tolerability


Composition : Pitavastatin 2mg + Ezetimibe 10mg

Form : Tablets / Pack : 10’s / Type : ALU-ALU

Description : Ezetimibe plus statin therapy in ACS patients with dyslipidemia decreased LDL-C and sitosterol levels more than statin therapy solo. Sitosterol Elevation was predictor of poor response to aggressive lipid lowering treatment in ACS patients - journal of Lipids Volume 2015 Study demonstrated for the first time that co-administration of ezetimibe 10mg enhanced proteinuria-lowering effects of pitavastatin 2mg. in non-diabetic CKD patients partly via a cholesterol-independent manner, Ezetimibe may have pleiotropic actions that could contribute to reno-protective properties of this lipid-lowering agent - Clinical Pharmacokinetics, May 2005, Volume 44, Issue 5, pp 467-494

View more products with following salts